Scarica l'app Stockscreener
88.41
0.10%
-0.09
Dopo l'orario di chiusura:
88.45
0.04
+0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$88.50
Aprire:
$88.64
Volume 24 ore:
41.63M
Relative Volume:
3.09
Capitalizzazione di mercato:
$153.99B
Reddito:
$45.13B
Utile/perdita netta:
$6.28B
Rapporto P/E:
24.63
EPS:
3.5895
Flusso di cassa netto:
$7.38B
1 W Prestazione:
-1.38%
1M Prestazione:
+0.57%
6M Prestazione:
-29.34%
1 anno Prestazione:
-33.23%
Intervallo 1D:
$87.76
$89.44
Intervallo di 1 settimana:
$87.07
$91.58
Portata 52W:
$81.97
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
3 US Dividend Growth Stocks With Balance Sheet And Payout Focus - simplywall.st
Whistleblower Alleges Medical Giant Bribed Hawaiʻi Provider - Honolulu Civil Beat
Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS Insider - GlobeNewswire Inc.
Citi Believes Abbott (ABT) Shares are Undervalued Relative to Business Segments - Insider Monkey
Abbott Laboratories Raised Prices, Prompting Sales Slump - WSJ
Ultrahuman M2 Live: Glucose Tracking Without a Prescription Using Abbott's Lingo Launches in the U.S. - Basic Tutorials
Why Abbott’s Libre Sense glucose sport biosensor keeps endurance athletes wired in - AD HOC NEWS
Abbott Laboratories director John Stratton buys $173,640 in shares - Investing.com
Director at Abbott (NYSE: ABT) buys 2,000 shares in open market - Stock Titan
Abbott Laboratories StockChart focus as shares test support - AD HOC NEWS
Ultrahuman Launches M2 Live in U.S. With Abbott Lingo™ CGM Integration - Digital Health News
Ultrahuman launches M2 Live with Abbott's Lingo glucose sensor - t2ONLINE
Abbott Laboratories stock underperforms Wednesday when compared to competitors - MarketWatch
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott's CGM Growth Story Stays Intact Despite Q1 Moderation - Yahoo Finance
Abbott Laboratories Stock Capital Return Hits $28 Bil - Trefis
Julie Johnson from Texas’s 32nd District Sells Shares in Abbott Laboratories and Accenture - Investing.com
Big Claims, Little Kids: Recent SDNY Decision Highlights Risks in Advertising (via Passle) - Frankfurt Kurnit Klein & Selz
Hormuz Reopening Trade: 20 Large-Caps Still Below Pre-War LevelsAbbott Laboratories (NYSE:ABT), PepsiC - Benzinga
Texas Rep. Julie Johnson Sold Up to $30K Worth of Abbott Laboratories Stock - Benzinga
How Investors May Respond To Abbott (ABT) Dividend And CE Mark For Dual Glucose‑Ketone Sensor - Yahoo Finance
Can S&P 500 Healthcare Giant Abbott Boost Growth With Libre Duo? - Kalkine Media
How Investors Are Reacting To Abbott (ABT) Pairing Libre Duo Launch With Its Latest Dividend Approval - simplywall.st
Abbott Laboratories (ABT): One of the Best Bargain Stocks to Buy in June - Insider Monkey
Abbott Laboratories Stock (US0028241000): Quiet trading day keeps healthcare name in focus - AD HOC NEWS
Is Abbott (ABT) the Best Longevity Stock to Buy Now? - Insider Monkey
Abbott Laboratories (ABT) Announces Quarterly Dividend of $0.63 - GuruFocus
Abbott Laboratories declares $0.63 dividend - MSN
Abbott Laboratories stock underperforms Friday when compared to competitors - MarketWatch
Abbott Laboratories Keeps Quarterly Dividend at $0.63 a Share, Payable Aug. 17 to Holders of Record as of July 15 - marketscreener.com
Abbott Laboratories Declares Quarterly Cash Dividend, Payable on August 17, 2026 - marketscreener.com
Abbott recalls heart device monitoring system due to malfunction risk - Cardiovascular Business
Abbott Laboratories Stock (US0028241000): Valuation metrics in focus for S&P 500 healthcare name - AD HOC NEWS
Abbott Laboratories Stock 12‑Month Price Target Cut to $115.5, Implies 29% Upside - TradingView
BofA Securities Maintains Abbott Laboratories(ABT.US) With Buy Rating, Cuts Target Price to $102 - 富途牛牛
BofA Adjusts Price Target on Abbott Laboratories to $102 From $120 - marketscreener.com
Abbott Laboratories seen as strong buy with 21.8–39.4% upside amid undervaluation and growth prospects. - Pluang
Abbott Laboratories (ABT) Stock Valuation Check After Recent Mixed Performance - simplywall.st
Abbott Laboratories $ABT Shares Bought by Parnassus Investments LLC - MarketBeat
IFM Investors Pty Ltd Has $45.53 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Remains Structurally Undervalued (NYSE:ABT) - Seeking Alpha
Abbott Labs is heavily oversold, says Powers Advisory Group's Matt Powers - MSN
Elfun Trusts Exits Abbott Laboratories, Impacting Portfolio by -1.97% - GuruFocus
Smithbridge Asset Management Inc. DE Raises Holdings in Abbott Laboratories $ABT - MarketBeat
Illinois Municipal Retirement Fund Has $28.27 Million Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Dorsey & Whitney Trust CO LLC - MarketBeat
Better medical device stock right now: Abbott Laboratories vs. Dexcom - MSN
This is Why Abbott Laboratories (ABT) is One of the Best Deep Value Stock to Invest In - Yahoo Finance
Abbott Offered Faulty Health Plan Option, Ex-Worker Says - Law360
Abbott Diabetes And Cancer Milestones Contrast With Prolonged Share Price Weakness - Yahoo Finance
Abbott (ABT) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):